Advanced in Li-Fraumeni Syndrome

Dr. John P. Stoutenburg

Hematology Oncology | Hematology | Oncology
Glens Falls Hospital Inc
79 N St, Granville Medical Center, 
Granville, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Li-Fraumeni Syndrome
Glens Falls Hospital Inc
79 N St, Granville Medical Center, 
Granville, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Stoutenburg is a Hematologist Oncology specialist and a Hematologist in Granville, New York. Dr. Stoutenburg is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Bone Marrow Aspiration.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Saratoga Hospital
Glens Falls Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

GLENS FALLS HOSPITAL INC
79 N St, Granville Medical Center, Granville, NY 12832
Other Locations
GLENS FALLS HOSPITAL INC
100 Park St, Glens Falls Hospital Credentialing, Glens Falls, NY 12801
GLENS FALLS HOSPITAL INC
1134 State Route 29, Greenwich, NY 12834

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Advanced in Li-Fraumeni Syndrome
Dr. Heidi E. Godoy
Gynecologic Oncology | Oncology
Advanced in Li-Fraumeni Syndrome
Dr. Heidi E. Godoy
Gynecologic Oncology | Oncology

New York Oncology Hematology PC

400 Patroon Creek Blvd, Suite 1, 
Albany, NY 
 (57.3 miles away)
518-489-0444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Heidi Godoy is a Gynecologic Oncologist and an Oncologist in Albany, New York. Dr. Godoy is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery.

Advanced in Li-Fraumeni Syndrome
Dr. Ami M. Negandhi
Hematology Oncology | Surgical Oncology | Oncology
Advanced in Li-Fraumeni Syndrome
Dr. Ami M. Negandhi
Hematology Oncology | Surgical Oncology | Oncology

New York Oncology Hematology PC

43 New Scotland Ave, 
Albany, NY 
 (58.6 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ami Negandhi is a Hematologist Oncology specialist and a Surgical Oncologist in Albany, New York. Dr. Negandhi is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Lung Cancer.

Advanced in Li-Fraumeni Syndrome
Dr. Ilana Cass
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Li-Fraumeni Syndrome
Dr. Ilana Cass
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Mary Hitchcock Memorial Hospital

1 Medical Ctr Dr, 
Lebanon, NH 
 (52.9 miles away)
603-650-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ilana Cass is a Gynecologic Oncologist and an Oncologist in Lebanon, New Hampshire. Dr. Cass is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Testicular Yolk Sac Tumor, Salpingo-Oophorectomy, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stoutenburg's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile